Debiopharm International

Diamond Sponsor

Debiopharm, an innovation-focused, Swiss biopharmaceutical company is one of the few privately owned companies developing new antibiotics to combat hard-to-treat infections. Through their unique partnership-based business model, the company is advancing early stage through phase II research of novel, pathogen-specific antibiotics, with afabicin, specifically targeting staphylococci spp., being the most clinically advanced for the treatment of Bone & Joint infections. As a result of highly selectivity, FabI inhibitors specifically target selected pathogens while preserving intestinal microbiota while meeting all four WHO 2020 innovativeness criteria: new chemical class, new target, new mode of action and no cross-resistance to other antibiotic classes.



GET INVOLVED AT THE

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


Semen Sen

semen.sen@terrapinn.com
+1 646.619.1793

 

 

To Speak

 


Emma Goaley

emma.goaley@terrapinn.com
+1 646.400.2576

 

 

Press & Media Partnerships

 


Ipek Coskun

ipek.coskun@terrapinn.com
+1 407.421.5818